Glenmark Launches Adapalene Gel Pump Packs in US, Eyes USD 45.8 Mn OTC Market

Glenmark’s Adapalene Gel USP, 0.1% contains the same active ingredient as Differin® Gel, 0.1%, according to the company. The new pump-pack format is intended to provide a convenient dispensing option for consumers.

According to Nielsen syndicated data for the 52-week period ended September 5, 2026, the US Differin Gel, 0.1% OTC market recorded annual sales of approximately USD 45.8 million. The market figure includes the brand and all available therapeutic equivalents.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, Glenmark, said, “The introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio. This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs.

The product is available in 15 g and 45 g pump-pack presentations in the US.

Glenmark said its Adapalene Gel USP, 0.1% is marketed only for the indications listed in its approved Drug Facts label.

The company clarified that its product is not manufactured or distributed by Galderma Laboratories, L.P. or Galderma Holding S.A., the distributor of Differin Gel and owner of the Differin trademark, respectively.

Glenmark Pharmaceuticals is a research-led pharmaceutical company with a focus on respiratory, dermatology and oncology. The company has a commercial presence across more than 80 countries and operates manufacturing facilities and research centres across multiple regions.